NCT01903252View on ClinicalTrials.gov

TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)

PHASE3CompletedINTERVENTIONAL
Enrollment

817

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

November 30, 2016

Conditions
Acute Ulcerative Colitis
Interventions
DRUG

TP05

3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)

DRUG

Asacol 400 mg

3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)

Trial Locations (1)

4310

Tillotts Pharma AG, Rheinfelden

All Listed Sponsors
lead

Tillotts Pharma AG

INDUSTRY

NCT01903252 - TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC) | Biotech Hunter | Biotech Hunter